BioLife Solutions (NASDAQ: BLFS) Mathew sells 405 shares under 10b5-1 plan

Rhea-AI Filing Summary

BioLife Solutions executive Aby J. Mathew reported a small insider sale of company stock. On 01/06/2026, the EVP & Chief Scientific Officer sold 405 shares of BioLife Solutions common stock at a price of $25.59 per share. After this transaction, he directly held 349,350 shares of the company’s common stock.

The sale was made under a pre-arranged Rule 10b5-1(c) trading plan that became effective on 01/03/2023, and was carried out to satisfy tax withholding obligations arising from the vesting of restricted stock.

Insider Trade Summary

Net Seller: 405 shares ($10,364)

Net Sell 1 txn

Insider Mathew Aby J.

Role EVP & Chief Scientific Officer

Sold 405 shs ($10K)

Type	Security	Shares	Price	Value
Sale	Common Stock	405	$25.59	$10K

Holdings After Transaction: Common Stock — 349,350 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mathew Aby J.

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/06/2026		S(1)		405	D	$25.59	349,350	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported herein was made pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 01-03-2023 to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.

Remarks:

	/s/ Aby J. Mathew	01/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider trading BioLife Solutions (BLFS) stock in this filing?

The reporting person is Aby J. Mathew, who serves as EVP & Chief Scientific Officer of BioLife Solutions.

How many BioLife Solutions (BLFS) shares did Aby J. Mathew sell and at what price?

On 01/06/2026, Aby J. Mathew sold 405 shares of BioLife Solutions common stock at a price of $25.59 per share.

How many BioLife Solutions (BLFS) shares does Aby J. Mathew own after this transaction?

Following the reported sale, Aby J. Mathew beneficially owned 349,350 shares of BioLife Solutions common stock, held directly.

Was the BioLife Solutions (BLFS) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sale was made under a Rule 10b5-1(c) trading plan adopted by the reporting person, effective 01-03-2023.

Why did Aby J. Mathew sell BioLife Solutions (BLFS) shares in this Form 4?

According to the footnote, the sale was made to satisfy tax withholding obligations related to the vesting of restricted stock.

Is this BioLife Solutions (BLFS) Form 4 filing for derivative securities?

No. The reported transaction involves common stock in Table I. Table II for derivative securities shows no entries.